Top Story

Exam of numerous tissues shows no significant difference in staging thin melanomas

January 27, 2015

The optimal number of sections to assess in staging thin melanomas without ulceration was three, with no significant difference in examining numerous tissue sections, according to recent study results.

Researchers in New Zealand conducted a search on the Pathlab database and included 71 cases of cutaneous melanomas 1 mm or less in Breslow thickness that were diagnosed between Jan. 1, 2012, and June 30, 2013. The researchers retrospectively retrieved and reviewed slides to compare the identification of the first dermal tumor mitotic figure, if present, at four checkpoints, including the examined first, third, fifth or tenth tissue section.

Mary-Margaret Chren, MD In the Journals

Some patients with keratinocyte carcinoma may have lower risk for subsequent tumors

January 23, 2015
A subset of patients who develop keratinocyte carcinoma may not be at risk for subsequent tumors, study results suggest.Mary-Margaret Chren, MD, of the department of…
In the Journals

Children of melanoma survivors do not adequately protect themselves from sun

January 22, 2015
Children of melanoma survivors do not adhere to optimal sun protection recommendations, as more than 40% of those individuals experienced a sunburn in the past year…
Erikka Loftfield, MPH In the Journals

Higher coffee consumption shows ties to decreased melanoma risk

January 22, 2015
People who consumed at least four cups of caffeinated coffee per day had a lower risk of malignant melanoma, according to recently published study results.Erikka
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
CME
PD-1 Antibodies

PD-1 Antibodies

This activity is supported by educational grants from Bristol-Myers Squibb, Delcath Systems, Inc., Merck & Co., Inc., OncoSec Medical, Inc., Prometheus and Provectus Pharmaceuticals, Inc.

This activity will review data on the efficacy, safety, and response patterns observed with PD-1 in patients with…
More »

Filter By:

In the Journals

Exam of numerous tissues shows no significant difference in staging thin melanomas

January 27, 2015
The optimal number of sections to assess in staging thin melanomas without ulceration was three, with no significant difference in examining numerous…
Mary-Margaret Chren, MD In the Journals

Some patients with keratinocyte carcinoma may have lower risk for subsequent tumors

January 23, 2015
A subset of patients who develop keratinocyte carcinoma may not be at risk for subsequent tumors, study results suggest.Mary-Margaret Chren
In the Journals

Children of melanoma survivors do not adequately protect themselves from sun

January 22, 2015
Children of melanoma survivors do not adhere to optimal sun protection recommendations, as more than 40% of those individuals experienced a sunburn…
Erikka Loftfield, MPH In the Journals

Higher coffee consumption shows ties to decreased melanoma risk

January 22, 2015
People who consumed at least four cups of caffeinated coffee per day had a lower risk of malignant melanoma, according to recently published study…
In the Journals

VE1 immunohistochemical analysis effectively detects BRAF V600E mutations

January 21, 2015
VE1 immunohistochemical analysis to detect BRAF V600E mutations in primary and metastatic cutaneous malignant melanomas was found to be useful and…
In the Journals

Subset of patients less likely to develop subsequent keratinocyte carcinoma

January 19, 2015
The risk for subsequent keratinocyte carcinoma was significantly lower in a subset of patients after their first lifetime tumor diagnosis compared…

Cipher Pharmaceuticals acquires Melanovus Oncology's assets

January 13, 2015
Cipher Pharmaceuticals announced its acquisition of the assets of Melanovus Oncology, including seven preclinical compounds for treating melanoma and…
In the Journals

Ipilimumab demonstrates long-term survival benefit in advanced melanoma

January 5, 2015
Some patients with advanced melanoma treated with ipilimumab continued to derive a survival benefit at least 5 years after treatment, according to…
In the Journals

Changes in nevi were poor predictors of melanoma in children

December 26, 2014
Monitoring changes in nevi may not be a useful approach to melanoma detection in children and may lead to unnecessary biopsies in this population…
Richard Pazdur, MD FDA News

FDA approves Opdivo for treatment of advanced melanoma

December 22, 2014
The U.S. Food and Drug Administration has granted accelerated approval to Opdivo as treatment for patients with unresectable and metastatic melanoma…
More Headlines »
morganatic-roan